Drugs / Triptorelin
Triptorelin
also known as
Triptorelin acetate · Decapeptyl · triptorelin pamoate · Arvekap · Gonapeptyl · Decapeptyl SR · Diphereline · Pamorelin · +16 more
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | EU (EMA) | Decapeptyl® | prostate cancer, hereditary, X-linked 3 | 2008-09-25 | “announces the filing of an application with the European Agencies for the approval of its new 6-month formulation of Decapeptyl®” debiopharm.com ↗ |
| Filed | US (FDA) | — | prostate cancer, hereditary, X-linked 3 | — | “Debiopharm has also developed a 6-month formulation of triptorelin, which has been submitted to the European and the U.S. regulatory authorities” debiopharm.com ↗ |
Trials 112 · started per year
today
1
1
1
8
2
4
4
3
6
2
1
4
10
6
7
2
6
7
3
2
3
3
7
3
5
3
7
19971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial · 1 met primary | ||||||
| Phase 0 | NCT03511196 | Sep 2018 → Jun 2022 overdue | prostate adenocarcinoma | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | Met primary |
| Phase 11 trial | ||||||
| Phase 1 | NCT04189900 | Apr → May 2019 | — | Parc de Salut Mar | Completed | No outcome recorded |
| Phase 1/22 trials · 1 missed | ||||||
| Phase 1/2 | NCT07653282 | Aug 2026 → Aug 2027 expected | — | Assiut University | Not yet recruiting | Missed primary |
| Phase 1/2 | NCT04616729 | Nov 2022 → Nov 2025 | female breast carcinoma | University Hospital Brussels | Unknown | No outcome recorded |
| Phase 224 trials · 2 met primary | ||||||
| Phase 2 | NCT07569315 | Jun 2026 → Dec 2027 expected | infertility disorder | Bedaya Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07569302 | Jun 2026 → Dec 2027 expected | infertility disorder | Bedaya Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07569289 | Jun 2026 → Dec 2027 expected | infertility disorder | Bedaya Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07455903 | Apr 2026 → Oct 2029 expected | prostate carcinoma | Baptist Health South Florida | Recruiting | No outcome recorded |
| Phase 2 | NCT06225284 | Aug 2024 → Dec 2026 expected | triple-negative breast carcinoma | National Taiwan University Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05896566 | Jan 2024 → Sep 2025 | breast cancer | ETOP IBCSG Partners Foundation | Completed | No outcome recorded |
| Phase 2 | NCT06146413 | Dec 2023 → Mar 2025 | infertility disorder | Bedaya Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04407065 | May → Dec 2020 | female infertility | Riyadh Fertility and Reproductive Health center | Unknown | No outcome recorded |
| Phase 2 | NCT04407052 | May → Dec 2020 | female infertility | Riyadh Fertility and Reproductive Health center | Unknown | No outcome recorded |
| Phase 2 | NCT03536234 | Sep 2018 → Aug 2021 | HIV infectious disease | Immune System Regulation AB | Unknown | No outcome recorded |
| Phase 2 | NCT02972060 | Dec 2017 → Jan 2023 overdue | prostate cancer | European Organisation for Research and Treatment of Cancer - EORTC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03279250 | Oct 2017 → May 2021 | prostate adenocarcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT04659551 | Oct 2017 → May 2020 | breast cancer | Veneto Institute of Oncology IRCCS | Completed | No outcome recorded |
| Phase 2 | NCT01969578 | Sep 2015 → Aug 2023 | salivary gland cancer | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 2 | NCT02244151 | Sep 2014 → Feb 2018 | female reproductive system disorder | La Fe Health Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT02005887 | Feb 2014 → Aug 2017 | invasive breast carcinoma | ETOP IBCSG Partners Foundation | Completed | Met primary |
| Phase 2 | NCT02113553 | May 2013 → May 2016 | breast cancer | Armando Santoro, MD | Terminated | No outcome recorded |
| Phase 2 | NCT03397537 | Sep 2012 → Jul 2017 | hormone receptor-positive breast cancer | Guangdong Provincial People's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01374087 | Nov 2011 → Dec 2014 | prostate cancer | Ipsen | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01257425 | Dec 2010 → Feb 2012 | prostate cancer | Ipsen | Completed | No outcome recorded |
| Phase 2 | NCT00528866 | Apr 2008 → Dec 2013 | prostate cancer | Radiation Therapy Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00444639 | Feb 2007 → Feb 2008 | prostate cancer | Ipsen | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00090844 | Jul 2004 → May 2008 | breast cancer, poisoning | University of South Florida | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00124514 | Jun 2003 → Mar 2014 | systemic lupus erythematosus | Children's Hospital Medical Center, Cincinnati | Completed | Met primary |
| Phase 2/35 trials · 1 missed | ||||||
| Phase 2/3 | NCT07319429 | Jan 2026 → Dec 2027 expected | endometrial cancer, infertility disorder | Fudan University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04753177 | Jan 2021 → Jan 2023 | — | Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary | Unknown | No outcome recorded |
| Phase 2/3 | NCT02856048 | Nov 2016 → Feb 2021 | Ewing sarcoma, chemotherapy-induced toxicity, lymphoma, osteosarcoma | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| Phase 2/3 | NCT01603420 | Jul 2012 → May 2014 | prostate cancer | Proton Collaborative Group | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT01160315 | Jul 2002 → Jun 2010 | lymphoma, primary ovarian failure | Erasme University Hospital | Completed | Missed primary |
| Phase 337 trials · 3 met primary · 7 missed | ||||||
| Phase 3 | NCT06795191 | Jun 2025 → Nov 2027 | prostate cancer | Foresee Pharmaceuticals Co., Ltd. | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT06513962 | Feb 2025 → Oct 2029 expected | cancer, hematopoietic and lymphoid system neoplasm | Children's Oncology Group | Recruiting | No outcome recorded |
| Phase 3 | NCT07816562 | Sep 2024 → Jul 2027 expected | ovarian dysfunction | Fundación para la Investigación del Hospital Clínico de Valencia | Recruiting | No outcome recorded |
| Phase 3 | NCT06150703 | Jun 2024 → Sep 2027 expected | — | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT05328258 | Mar 2023 → Jan 2028 expected | Ewing sarcoma, acute leukemia, female breast carcinoma, lymphoma +2 | Kenny Rodriguez-Wallberg | Recruiting | No outcome recorded |
| Phase 3 | NCT05590793 | Nov 2022 → Aug 2024 | metastatic prostate carcinoma | Ipsen | Completed | No outcome recorded |
| Phase 3 | NCT05458856 | Aug 2022 → Jul 2024 | prostate cancer | Ipsen | Completed | No outcome recorded |
| Phase 3 | NCT05397795 | Jun → Dec 2022 | infertility disorder | Alexandria University | Unknown | No outcome recorded |
| Phase 3 | NCT03940807 | Apr 2022 → Jan 2025 | adenomyosis | University Hospital, Toulouse | Withdrawn | No outcome recorded |
| Phase 3 | NCT05029622 | Aug 2021 → Aug 2022 | central precocious puberty | Ipsen | Completed | No outcome recorded |
| Phase 3 | NCT04736602 | Mar 2021 → Feb 2022 | central precocious puberty | Ipsen | Completed | No outcome recorded |
| Phase 3 | NCT04224818 | Jul 2018 → Aug 2019 | ovarian dysfunction | American University of Beirut Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT03232281 | Jul 2017 → May 2019 | endometriosis | Ipsen | Completed | Met primary |
| Phase 3 | NCT02732808 | Sep 2014 → Apr 2016 | female infertility | Royan Institute | Completed | No outcome recorded |
| Phase 3 | NCT03039049 | Mar 2014 → Mar 2017 | infertility disorder | Centre Hospitalier Universitaire Ibn Rochd | Completed | No outcome recorded |
| Phase 3 | NCT02053779 | Mar 2014 → Mar 2017 | infertility disorder | Centre Hospitalier Universitaire Ibn Rochd | Completed | No outcome recorded |
| Phase 3 | NCT01715129 | Jan → Oct 2013 | prostate cancer | Ipsen | Completed | No outcome recorded |
| Phase 3 | NCT01656161 | Jul 2012 → Aug 2013 | prostate cancer | Debiopharm International SA | Completed | No outcome recorded |
| Phase 3 | NCT01467882 | Apr 2012 → Aug 2013 | central precocious puberty | Debiopharm International SA | Completed | No outcome recorded |
| Phase 3 | NCT01492972 | Jan 2012 → Dec 2027 expected | prostate cancer | Proton Collaborative Group | Recruiting | No outcome recorded |
| Phase 3 | NCT01368588 | Jul 2011 → Apr 2025 overdue | prostate cancer | Radiation Therapy Oncology Group | Active not recruiting | Missed primary |
| Phase 3 | NCT01020448 | Nov 2009 → Nov 2011 | prostate cancer | Ipsen | Completed | No outcome recorded |
| Phase 3 | NCT00936390 | Sep 2009 → Oct 2020 | prostate cancer | Radiation Therapy Oncology Group | Completed | Missed primary |
| Phase 3 | NCT00667069 | Apr 2008 → Apr 2020 | prostate cancer | UNICANCER | Completed | Missed primary |
| Phase 3 | NCT00909844 | Apr 2008 → Apr 2015 | precocious puberty | Ipsen | Completed | No outcome recorded |
| Phase 3 | NCT00567580 | Feb 2008 → Jul 2018 | prostate cancer | Radiation Therapy Oncology Group | Unknown | Met primary |
| Phase 3 | NCT00659373 | Dec 2007 → Dec 2014 | breast cancer, sleep disorder | ETOP IBCSG Partners Foundation | Completed | Missed primary |
| Phase 3 | NCT00564850 | Oct 2007 → Oct 2010 | precocious puberty | Ipsen | Completed | No outcome recorded |
| Phase 3 | NCT00415246 | Nov 2006 → Oct 2007 | prostate cancer | Ipsen | Terminated | No outcome recorded |
| Phase 3 | NCT01007851 | Sep 2006 → Dec 2007 | infertility disorder | V.K.V. American Hospital, Istanbul | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00751790 | Jul 2006 → Aug 2007 | prostate neoplasm | Debiopharm International SA | Completed | No outcome recorded |
| Phase 3 | NCT00066690 | Dec 2003 → May 2014 | estrogen-receptor positive breast cancer, female breast carcinoma, progesterone-receptor positive breast cancer | ETOP IBCSG Partners Foundation | Completed | Missed primary |
| Phase 3 | NCT00104741 | Sep 2003 → Oct 2015 | prostate cancer | UNICANCER | Completed | No outcome recorded |
| Phase 3 | NCT00311636 | Sep 2003 → Jan 2008 | breast cancer | Gruppo Italiano Mammella (GIM) | Completed | Met primary |
| Phase 3 | NCT00066807 | Aug 2003 → Dec 2006 | breast cancer | ETOP IBCSG Partners Foundation | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT00003734 | Dec 1998 → ? | prostate cancer | St. Luke's Hospital, Ireland | Unknown | Missed primary |
| Phase 3 | NCT00003026 | Apr 1997 → Sep 2001 | prostate cancer | European Organisation for Research and Treatment of Cancer - EORTC | Completed | Missed primary |
| Phase 426 trials · 1 met primary · 2 missed | ||||||
| Phase 4 | NCT07696351 | Aug 2025 → Dec 2026 expected | endometriosis, infertility disorder | Li-jun Ding | Recruiting | No outcome recorded |
| Phase 4 | NCT06487143 | Jul 2024 → Dec 2026 expected | central precocious puberty | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05286554 | Mar 2022 → Oct 2023 | female infertility | Alexandria University | Completed | No outcome recorded |
| Phase 4 | NCT04248621 | Jan 2020 → Apr 2022 | prostate neoplasm | Wonju Severance Christian Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03809221 | Feb 2019 → Sep 2020 | female infertility | Peking University People's Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03169166 | Mar 2017 → Jul 2021 | female infertility | American University of Beirut Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02715232 | Feb 2017 → Dec 2020 | body integrity dysphoria | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 4 | NCT03115307 | Jan 2017 → Nov 2019 | female infertility | Tampere University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02825290 | Jul 2016 → Jun 2017 | — | Sheba Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT02655146 | Dec 2015 → Dec 2016 | infertility disorder | Chong Qing Reproducive and Genetic Institute | Unknown | No outcome recorded |
| Phase 4 | NCT02201914 | Jan → Oct 2014 | — | Bioroma | Unknown | No outcome recorded |
| Phase 4 | NCT02070198 | Dec 2013 → Nov 2014 | female infertility | Bioroma | Unknown | No outcome recorded |
| Phase 4 | NCT02620124 | May 2013 → Apr 2015 | infertility disorder | Turku University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01714648 | Nov 2012 → Jan 2014 | ovarian hyperstimulation syndrome | Elisha Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT01638026 | Sep 2012 → Jul 2017 | infertility disorder | HaEmek Medical Center, Israel | Completed | No outcome recorded |
| Phase 4 | NCT01673984 | Aug 2012 → Feb 2014 | prostate cancer | Ipsen | Terminated | No outcome recorded |
| Phase 4 | NCT01500863 | Nov 2011 → May 2012 | ovarian hyperstimulation syndrome | IVI Madrid | Completed | No outcome recorded |
| Phase 4 | NCT00735852 | Dec 2008 → May 2016 | endometriosis | Sheffield Teaching Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| Phase 4 | NCT00840944 | Jan 2008 → Jan 2024 | isolated short stature | Belgian Study Group for Pediatric Endocrinology | Unknown | No outcome recorded |
| Phase 4 | NCT00417183 | Sep 2005 → Jun 2007 | infertility disorder | Eugonia | Unknown | No outcome recorded |
| Phase 4 | NCT00461916 | May 2005 → Dec 2006 | infertility disorder | Tehran University of Medical Sciences | Completed | Missed primary |
| Phase 4 | NCT00503217 | Feb 2005 → Dec 2007 | — | Instituto Valenciano de Infertilidad, IVI VALENCIA | Completed | No outcome recorded |
| Phase 4 | NCT00417144 | Nov 2003 → May 2007 | ovarian hyperstimulation syndrome, polycystic ovary syndrome | Eugonia | Unknown | Missed primary |
| Phase 4 | NCT00415792 | Nov 2003 → Jul 2005 | infertility disorder | Eugonia | Unknown | No outcome recorded |
| Phase 4 | NCT00417066 | Sep 2003 → Jul 2006 | female infertility, primary ovarian failure | Eugonia | Completed | Met primary |
| Phase 4 | NCT00438217 | — | central precocious puberty | University of Pisa | Unknown | No outcome recorded |
| Phase not applicable16 trials · 2 missed | ||||||
| — | NCT07861399 | Sep 2026 → Aug 2028 expected | — | Al-Azhar University | Recruiting | No outcome recorded |
| — | NCT05746806 | Mar 2023 → Nov 2027 expected | prostate carcinoma | Insel Gruppe AG, University Hospital Bern | Active not recruiting | No outcome recorded |
| — | NCT05567731 | Oct 2022 → Dec 2023 | infertility disorder | Tanta University | Completed | No outcome recorded |
| — | NCT02940535 | Dec 2016 → Dec 2019 | anovulation, female infertility | Navy General Hospital, Beijing | Unknown | No outcome recorded |
| — | NCT05945407 | Aug 2016 → Dec 2023 overdue | endometrial cancer, endometrial endometrioid adenocarcinoma | Peking University People's Hospital | Recruiting | No outcome recorded |
| — | NCT02681536 | Feb → Sep 2016 | infertility disorder | Woman's Health University Hospital, Egypt | Unknown | No outcome recorded |
| — | NCT03006406 | Jan 2016 → Jan 2017 | — | The First Affiliated Hospital of Zhengzhou University | Unknown | No outcome recorded |
| — | NCT02477566 | Dec 2014 → Dec 2016 | polycystic ovary syndrome | Nanjing University | Unknown | No outcome recorded |
| — | NCT02400801 | Jun 2013 → Dec 2017 | endometriosis, female infertility | Universitaire Ziekenhuizen KU Leuven | Completed | Missed primary |
| — | NCT01873378 | Jan 2013 → Aug 2015 | leiomyoma | Azienda Ospedaliera S. Maria della Misericordia | Completed | No outcome recorded |
| — | NCT02022241 | Jul 2012 → Dec 2015 | ovarian hyperstimulation syndrome | Chenshiling | Unknown | No outcome recorded |
| — | NCT01634724 | Jul 2012 | — | Nanjing University | Unknown | No outcome recorded |
| — | NCT01468441 | Sep 2011 → Mar 2012 | infertility disorder | Fertility - Assisted Fertilization Center | Completed | No outcome recorded |
| — | NCT00516490 | Sep 2006 → Jul 2007 | infertility disorder | V.K.V. American Hospital, Istanbul | Completed | Missed primary |
| — | NCT00375687 | Aug 2005 → Jan 2020 | prostate cancer | Kaunas University of Medicine | Unknown | No outcome recorded |
| — | NCT01764230 | Jan 2004 → Jul 2007 | Hodgkins lymphoma | Masaryk University | Completed | No outcome recorded |
| Comparator or background therapy87 trials | ||||||
| Phase 0 | NCT07389187 Background | Feb → Dec 2026 expected | castration-resistant prostate carcinoma | Shanghai Changzheng Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT07389174 Background | Feb 2026 → Jan 2027 expected | prostate adenocarcinoma | Shanghai Changzheng Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT05151016 Comparator | Dec 2021 → Dec 2023 | adenomyosis | Women's Hospital School Of Medicine Zhejiang University | Unknown | No outcome recorded |
| Phase 1 | NCT03192527 Background | Jun 2017 → Mar 2019 | female infertility | Alphamab Jilin Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04071574 Comparator | Feb 2018 → Aug 2019 | ectopic pregnancy, endometriosis, female infertility, hydrosalpinx +6 | Lebanese University | Completed | No outcome recorded |
| Phase 2 | NCT07268794 Background | Nov 2025 → Apr 2027 expected | metastatic prostate carcinoma, prostate adenocarcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07254429 Comparator | Oct 2025 → Dec 2027 expected | postmenopausal osteoporosis | Martin Blomberg Jensen | Recruiting | No outcome recorded |
| Phase 2 | NCT06832774 Background | Aug 2025 → Dec 2027 expected | metastatic prostate carcinoma | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT06528210 Background | Apr 2025 → Jun 2026 | prostate adenocarcinoma | OHSU Knight Cancer Institute | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT06734130 Background | Jan 2025 → Jan 2029 expected | metastatic prostate carcinoma | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07553988 Background | Oct 2024 → May 2026 overdue | prostate carcinoma | R-Pharm International, LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06378866 Comparator | Jun 2024 → Feb 2031 expected | castration-resistant prostate carcinoma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 2 | NCT05851547 Background | Nov 2023 → Jun 2027 expected | prostate neoplasm | Ottawa Hospital Research Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT05555017 Background | Feb 2023 → Nov 2024 | prostate cancer | The Netherlands Cancer Institute | Unknown | No outcome recorded |
| Phase 2 | NCT05982093 Comparator | Feb 2023 → Dec 2026 expected | hormone receptor-positive breast cancer | SOLTI Breast Cancer Research Group | Recruiting | No outcome recorded |
| Phase 2 | NCT05498272 Background | Feb 2023 → Aug 2026 overdue | BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, prostate adenocarcinoma | Rana McKay, MD | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05212857 Background | Apr 2022 → Feb 2024 | prostate cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT05189457 Background | Jan 2022 → Jul 2027 expected | prostate cancer | H. Lee Moffitt Cancer Center and Research Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04931342 Background | Oct 2021 → Feb 2028 expected | ovarian cancer | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04992026 Background | Jan 2021 → Dec 2024 | metastatic prostate carcinoma | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Completed | No outcome recorded |
| Phase 2 | NCT05406999 Background | Feb 2020 → Dec 2026 expected | prostate cancer | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Recruiting | No outcome recorded |
| Phase 2 | NCT03899077 Comparator | Apr 2019 → Aug 2025 | prostate cancer | Cancer Research Antwerp | Unknown | No outcome recorded |
| Phase 2 | NCT03944434 Background | Dec 2018 → Dec 2024 overdue | breast cancer | Fondazione Sandro Pitigliani | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04869371 Background | Dec 2018 → Dec 2020 | — | Hongqian Guo | Unknown | No outcome recorded |
| Phase 2 | NCT02278185 Comparator | Nov 2015 → Apr 2019 | prostate adenocarcinoma | University of Colorado, Denver | Completed | Missed primary |
| Phase 2 | NCT02742675 Background | Sep 2015 → Mar 2021 | prostate cancer | Fudan University | Unknown | No outcome recorded |
| Phase 2 | NCT01973842 Comparator | Feb 2014 → Jul 2016 | infertility disorder | Aristotle University Of Thessaloniki | Unknown | No outcome recorded |
| Phase 2 | NCT02461875 Background | May 2013 → Nov 2015 | ovarian hyperstimulation syndrome | Aljazeera Hospital | Unknown | Met primary |
| Phase 2 | NCT01732094 Background | Jul 2012 → May 2013 | infertility disorder, ovarian dysfunction | University Hospital Brussels | Completed | No outcome recorded |
| Phase 2 | NCT01732068 Background | Jul 2012 → May 2013 | infertility disorder, ovarian dysfunction | University Hospital Brussels | Completed | No outcome recorded |
| Phase 2/3 | NCT04787744 Background | Jul 2021 → Sep 2026 overdue | metastatic prostate carcinoma | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03139474 Comparator | Jun 2017 → Jun 2019 | female infertility | Assiut University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03353883 Comparator | Jun 2017 → Jun 2018 | female infertility | Benha University | Unknown | No outcome recorded |
| Phase 2/3 | NCT02685397 Background | Oct 2016 → Apr 2027 expected | castration-resistant prostate carcinoma | Sir Mortimer B. Davis - Jewish General Hospital | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT01590173 Comparator | Jan 2012 → Jul 2016 | infertility disorder | National and Kapodistrian University of Athens | Completed | No outcome recorded |
| Phase 3 | NCT07477626 Background | Mar 2026 → Dec 2033 expected | metastatic malignant neoplasm in the lymph nodes, prostate cancer | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT05879926 Comparator | Oct 2023 → Jan 2032 expected | breast cancer | NRG Oncology | Recruiting | No outcome recorded |
| Phase 3 | NCT05972902 Comparator | Jul → Dec 2023 | — | Beni-Suef University | Unknown | No outcome recorded |
| Phase 3 | NCT05781217 Comparator | Mar → Dec 2023 overdue | prostate cancer | Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic | Recruiting | No outcome recorded |
| Phase 3 | NCT05050084 Background | Dec 2021 → Nov 2026 expected | prostate adenocarcinoma | NRG Oncology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04484818 Background | Mar 2021 → Sep 2026 overdue | prostate carcinoma | ECOG-ACRIN Cancer Research Group | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04513717 Background | Jan 2021 → Dec 2033 expected | prostate adenocarcinoma | NRG Oncology | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04557059 Background | Nov 2020 → Aug 2029 expected | prostate neoplasm | Janssen Pharmaceutica N.V., Belgium | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04423211 Background | Oct 2020 → Dec 2032 expected | metastatic prostate carcinoma, prostate adenocarcinoma | ECOG-ACRIN Cancer Research Group | Recruiting | No outcome recorded |
| Phase 3 | NCT04181203 Background | Jan 2020 → Sep 2028 expected | prostate cancer | UNICANCER | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03678025 Background | Sep 2018 → Apr 2033 expected | prostate adenocarcinoma | SWOG Cancer Research Network | Recruiting | No outcome recorded |
| Phase 3 | NCT01546987 Background | May 2012 → Nov 2021 | prostate cancer | Radiation Therapy Oncology Group | Completed | Missed primary |
| Phase 3 | NCT01313273 Background | Jun 2011 → Jun 2013 | prostate cancer | Ipsen | Terminated | No outcome recorded |
| Phase 3 | NCT01402336 Comparator | Jun 2011 → Dec 2016 | infertility disorder, polycystic ovary syndrome | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01125488 Background | Mar 2008 → Mar 2009 | endometriosis | Taipei Veterans General Hospital, Taiwan | Unknown | No outcome recorded |
| Phase 3 | NCT00725491 Comparator | May 2007 → Dec 2008 | — | Organon and Co | Completed | Met primary |
| Phase 3 | NCT00288080 Background | Dec 2005 → Apr 2014 | prostate cancer | Radiation Therapy Oncology Group | Completed | Met primary |
| Phase 3 | NCT00412022 Background | Mar 2004 → Nov 2024 | breast cancer | National Cancer Institute, Naples | Unknown | Met primary |
| Phase 3 | NCT00066703 Background | Nov 2003 → Mar 2011 | breast cancer | ETOP IBCSG Partners Foundation | Completed | Met primary |
| Phase 3 | NCT00764166 Background | Jun 2003 → Nov 2009 | prostate adenocarcinoma | Assistance Publique - Hôpitaux de Paris | Unknown | Missed primary |
| Phase 3 | NCT00004054 Background | Jan 2000 → Apr 2010 | prostate cancer | Radiation Therapy Oncology Group | Completed | Missed primary |
| Phase 4 | NCT06763926 Comparator | Oct 2026 → Jan 2028 expected | — | Fundacion Dexeus | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06396390 Background | Aug 2024 → Jun 2026 overdue | infertility disorder | Nesta Clinic | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04157725 Comparator | Jun 2023 → Jan 2025 | infertility disorder, polycystic ovary syndrome | American University of Beirut Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT05321511 Comparator | Mar → Dec 2022 | ovarian dysfunction | Instituto Bernabeu | Unknown | No outcome recorded |
| Phase 4 | NCT04992468 Background | Oct 2021 → Apr 2023 | infertility disorder | Fundacion Dexeus | Completed | No outcome recorded |
| Phase 4 | NCT04724486 Comparator | Aug 2020 → Mar 2022 | infertility disorder | Damascus University | Completed | No outcome recorded |
| Phase 4 | NCT04727684 Comparator | Aug 2020 → Feb 2022 | infertility disorder, polycystic ovary syndrome | Damascus University | Completed | No outcome recorded |
| Phase 4 | NCT04724343 Comparator | Dec 2019 → Jan 2022 | infertility disorder | Damascus University | Completed | No outcome recorded |
| Phase 4 | NCT04727671 Comparator | Dec 2019 → Aug 2021 | infertility disorder, polycystic ovary syndrome | Damascus University | Completed | No outcome recorded |
| Phase 4 | NCT03784404 Comparator | Dec 2018 → Dec 2019 | ovarian endometriosis | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT03118830 Comparator | Apr → Nov 2017 | — | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT02821819 Background | Jan 2017 → Jan 2018 | infertility disorder | Instituto Bernabeu | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02312076 Comparator | Sep 2016 → Dec 2024 | infertility disorder | Mansoura University | Unknown | No outcome recorded |
| Phase 4 | NCT02312089 Comparator | Aug 2016 → Dec 2024 | infertility disorder | Mansoura University | Unknown | No outcome recorded |
| Phase 4 | NCT04008966 Comparator | Jul 2016 → Jun 2019 | — | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT02330770 Comparator | Jun 2016 → Dec 2024 | infertility disorder | Mansoura University | Unknown | No outcome recorded |
| Phase 4 | NCT02102646 Comparator | Apr 2014 → Oct 2015 | fatty liver disease, hypogonadism, metabolic syndrome X, prostate cancer | Herlev Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01753297 Comparator | Dec 2012 → Sep 2019 | prostate cancer | Ipsen | Completed | No outcome recorded |
| Phase 4 | NCT01581359 Comparator | Mar 2012 → Mar 2015 | endometriosis, infertility disorder | La Fe Health Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT01161563 Comparator | Jul 2010 → Apr 2011 | prostate cancer | Watson Pharmaceuticals | Completed | No outcome recorded |
| — | NCT06913075 Comparator | Jun → Jul 2026 overdue | adenomyosis | Indira IVF Hospital Pvt Ltd | Not yet recruiting | No outcome recorded |
| — | NCT06481696 Comparator | Jun 2024 → Dec 2025 | infertility disorder | Andros Day Surgery Clinic | Unknown | No outcome recorded |
| — | NCT07128394 Background | Feb 2024 → Sep 2026 overdue | female infertility | Nanjing University | Recruiting | No outcome recorded |
| — | NCT06581679 Comparator | Dec 2023 → Apr 2024 | adenomyosis | Zagazig University | Completed | No outcome recorded |
| — | NCT05112692 Comparator | Nov 2021 → Nov 2023 | polycystic ovary syndrome | Mansoura University | Unknown | No outcome recorded |
| — | NCT03684824 Background | Sep 2018 → Sep 2019 | — | Cairo University | Unknown | No outcome recorded |
| — | NCT04846218 Comparator | Dec 2016 → Jan 2020 | female infertility | Ain Shams University | Completed | No outcome recorded |
| — | NCT02635607 Background | Jan → Dec 2016 | female infertility | Chong Qing Reproducive and Genetic Institute | Unknown | No outcome recorded |
| — | NCT02208986 Comparator | Aug 2014 → Feb 2015 | — | Vietnam National University | Completed | No outcome recorded |
| — | NCT02022228 Background | Jul 2012 → Dec 2015 | ovarian hyperstimulation syndrome | Chenshiling | Unknown | No outcome recorded |
| — | NCT01565265 Comparator | Apr → Dec 2012 | female infertility | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 15
| Date | Issuer | Release |
|---|---|---|
| 2025-09-04 | Debiopharm International SA | Regulatory Debiopharm’S Pamorelin® Receives Swiss Approval for subcutaneous Administration, Enhancing Treatment Flexibility for Prostate Cancer Patients debiopharm.com ↗
Debiopharm ( ), an independently-owned Swiss biopharmaceutical company committed to developing tomorrow’s standard-of-care treatments to cure cancer and infectious diseases, announced that Swissmedic approved, as of May 16, 2025, the subcutaneous administration of Pamorelin® LA 3.75 mg and Pamorelin® LA 11.25 mg (triptorelin embonate) for the treatment of prostate cancer. |
| 2017-06-30 | Debiopharm International SA | Regulatory Debiopharm International SA and Arbor Pharmaceuticals, LLC Announce U.S. FDA Approval for Triptodur™, Triptorelin 6-month Formulation, in the Treatment of Central Precocious Puberty (CPP) debiopharm.com ↗
Debiopharm International SA, part of Debiopharm Group™, a Swiss-based global biopharmaceutical company, and Arbor Pharmaceuticals, LLC, a U.S.-based specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Triptodur™ for the treatment of pediatric patients 2 years and older with central precocious puberty (CPP). |
| 2017-04-11 | Xbrane Biopharma AB | Results Xbrane Biopharma reports positive in-vivo efficacy data on Spherotide xbrane.com ↗
Spherotide demonstrated no significant difference vs. the originator product on the clinically relevant endpoint, testosterone suppression 1 month after injection. |
| 2017-01-09 | Debiopharm International SA | Regulatory Debiopharm Group’s Triptorelin 6-month Formulation Receives Approval for the Treatment of Central Precocious Puberty (CPP) in Europe debiopharm.com ↗
triptorelin is the first 6-month GnRH agonist formulation approved for the treatment of CPP. |
| 2016-10-24 | Xbrane Biopharma AB | Regulatory Xbrane Biopharma AB: Positive outcome of inspection from Italian Medicines Agency – GMP approval of Xbrane’s Spherotide production facility is expected in Q1 2017 xbrane.com ↗
AIFA has now completed the inspection of the production facility with positive outcome. |
| 2015-05-19 | Debiopharm International SA | Results Debiopharm International SA Announces Phase III Positive Results for Triptorelin 6-month Formulation in the Management of Central Precocious Puberty (CPP) debiopharm.com ↗
The percentage of children with prepubertal LH levels exceeded 93% at each time point on-treatment and reached 98% at month 12 when all but one patient were suppressed. |
| 2009-10-13 | Debiopharm International SA | Regulatory Ipsen and Debiopharm Group announce that Decapeptyl® (triptorelin embonate) 6-month successfully completes the European Decentralised Procedure for the treatment of locally advanced or metastatic prostate cancer debiopharm.com ↗
announced that the 6-month sustained-release formulation of Decapeptyl® (triptorelin embonate 22.5 mg) successfully completed its European decentralised registration procedure involving nine countries: Germany (reference member state), France, Austria, Finland, Norway, Belgium, Denmark, Spain and The Netherlands. |
| 2009-07-21 | Debiopharm International SA | Regulatory Swissmedic grants Debiopharm marketing authorisation for Moapar® – A new therapeutic avenue for the treatment of sexual deviations debiopharm.com ↗
Swissmedic, has issued a marketing authorisation for Moapar® 11.25mg |
| 2008-11-14 | Debiopharm International SA | Regulatory Debiopharm announces U.S. NDA filing of Trelstar® 6-month formulation for locally advanced or metastatic prostate cancer debiopharm.com ↗
today announced that the New Drug Application (NDA) for the 6 month formulation of Trelstar® (triptorelin pamoate) has been accepted for filing by the United States (U.S.) Food and Drug Administration (FDA). |
| 2008-09-25 | Debiopharm International SA | Regulatory Debiopharm moves towards a new 6-month formulation of Decapeptyl® to further help prostate cancer patients debiopharm.com ↗
This submission in Europe of our first 6-month-formulation for the treatment of prostate cancer is another demonstration of Debiopharm’s commitment to supporting and enhancing the life of cancer patients. |
| 2008-02-12 | Debiopharm International SA | Results Clinical Update – Decapeptyl®/Trelstar® 6-Month Formulation in Advanced Prostate Cancer debiopharm.com ↗
These results show similar efficacy and safety to the already marketed 1- and 3-month formulations. |
| 2007-05-24 | Debiopharm International SA | Regulatory Salvacyl®/ Maopar® 3-month obtains european mutual recognition to treat sexual deviations debiopharm.com ↗ |
| 2006-06-20 | Debiopharm International SA | Regulatory Moapar® 3-months approved for the lowering of testosterone to castrate serum levels for control of sexual drive in adult men debiopharm.com ↗ |
| 2004-03-23 | Debiopharm International SA | Regulatory Debiopharm´s Pamorelin Long Acting, Formulated Using Debio® PLGA Technology, receives Final Marketing Autorisation in Germany debiopharm.com ↗
Debiopharm S.A., the independent drug-development company specialising in oncology, endocrinology, CNS and niche diseases, today announces that Pamorelin long acting (LA) 11.25mg, a three month formulation, was granted final marketing authorization in Germany on March 18, 2004 by the Bundesinstitut für Arzneimittel und Medizinprodukte, also known as BfArM. |
| 2001-07-05 | Debiopharm International SA | Regulatory Swiss drug developer Debiopharm announces FDA approval of Trelstar TM LA for therapeutic use debiopharm.com ↗
The Swiss-based pharmaceutical development company Debiopharm S.A., part of the Debio group, today announced that the FDA has granted marketing authorization for Debiopharm’s luteinizing hormone releasing hormone (LHRH) agonist, triptorelin pamoate, TRELSTAR TM LA, to treat advanced stage prostate cancer. |
All press releases naming this drug 45 releases
Evidence & citations 28 cited values
Every value below carries the sentence it was read from. 201 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Triptorelin | “All patients receive neoadjuvant androgen-deprivation therapy comprising bicalutamide orally (PO) once daily or flutamide PO thrice daily for 4-6 months, and luteinizing...” NCT01368588 ↗183“When one or two dominant follicles (18 mm in diameter) observed, the final stage of oocyte maturation will be induced with triptorelin 100 μg (Decapeptyl®; Ferring GmbH,...” NCT02732808 ↗ “This regimen consists of Androgen Deprivation Therapy (ADT) (e.g., Goserelin, Leuprorelin, Triptorelin, or Degarelix) combined with an oral Androgen Receptor (AR) inhibitor...” NCT07389174 ↗ “GnRHa (triptorelin,0.05mg/d) was injected stimulously with FSH before dominant follicles were ≥ 14 mm. When the diameter of one or more follicles was ≥ 14 mm, GnRHa...” NCT01634724 ↗ “Triptorelin at a dose 1 mg per day from the midluteal phase of the cycle preceding the treatment cycle to day 2 of the cycle then 0.5 milligram of triptorelin will be used...” NCT03139474 ↗ “A multi-center, randomized controlled clinical trial of the application of a shortened protocol of long-acting Triptorelin down-regulated prior to IVF/ICSI among patients with...” PMID 30572916 ↗ Dec 2018 “Group II (Dual trigger group) that included 80 women who received triggering in the form of 10,000 IU of HCG intramuscular injection in addition to GnRH agonist triptorelin 0.2...” NCT04008966 ↗ “the agonist group will receive Decapeptyl® 0.1 mg (triptorelin) starting in the mid-luteal phase of the natural cycle until downregulation until the day of ovulation induction” NCT01565265 ↗ “Pituitary suppression will be done using daily subcutaneous injection of triptorelin acetate ( Decapeptyl 0.1mg, Ferring, Germany). Starting from day 21 of the previous cycle” NCT03684824 ↗ “Ultra-long protocol group women will receive one intra-muscular administration of 11.25 mg GnRH agonist (triptorelin acetate) on the luteal phase of their menstrual cycle.” NCT03940807 ↗ “HCG (10000 IU /IM) and triptorelin (0.2 mg/S.C) are administered 36 hours before ovum pickup . Moreover, 0.1mg of triptorelin is administered 24 h prior to ovum pick-up.” NCT07569302 ↗ |
| Known as | Arvekap | “Arvekap 0.1mg (Triptorelin, Ipsen, France)” NCT00417144 ↗ |
| Known as | Decapeptyl | “When one or two dominant follicles (18 mm in diameter) observed, the final stage of oocyte maturation will be induced with triptorelin 100 μg (Decapeptyl®; Ferring GmbH,...” NCT02732808 ↗10“the agonist group will receive Decapeptyl® 0.1 mg (triptorelin) starting in the mid-luteal phase of the natural cycle until downregulation until the day of ovulation induction” NCT01565265 ↗ “In case of OHSS risk, the final oocyte maturation will be obtained by using a GnRH agonist (Triptorelin, Decapeptyl 0.1 mg, Ipsen S.p.A., Italy) 0.3 mg subcutaneously” NCT06481696 ↗ “Patients have a injection 0.1mg short-acting Triptorelin acetate (Decapeptyl®, Ferring, Germany) every day, 10-12 days before the next menstrual cycle.” NCT03809221 ↗ “One intramuscular injection of triptorelin (Decapeptyl®) 22.5mg performed once all baseline procedures and assessments have been completed.” NCT01020448 ↗ “Triptorelin (Decapeptyl®) - Treatment 8 months (pivotal study) followed by a treatment extension of 8 months (extension study)” NCT00415246 ↗ “Ovulation trigger: Triptorelin 0.2 mg (Decapeptyl®) + Recombinant human chorionic gonadotropin (rhCG) 250μg (Ovitrelle®)” NCT04992468 ↗ “GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom)” NCT04407052 ↗ “Triptorelin :Decapeptyl 0.1 mg (Ferring, Switzerland)” NCT05567731 ↗ “Drug: Triptorelin (Decapeptyl®)” NCT00444639 ↗ “Decapeptyl (Triptorelin)” NCT02940535 ↗ |
| Known as | Decapeptyl 0.1 mg | “GnRH agonist triptorelin 0.2 mg (Decapeptyl 0.1 mg; Ferring) subcutaneously.” NCT05397795 ↗ |
| Known as | DECAPEPTYL LP | “Triptorelin (DECAPEPTYL LP 3 mg, IPSEN)” NCT02856048 ↗ |
| Known as | Decapeptyl SR | “Triptorelin pamoate 11.25mg (Decapeptyl® SR)” NCT00564850 ↗1“Decapeptyl® SR 22.5mg (Triptorelin)” NCT01673984 ↗ |
| Known as | Dipherelin | “Patients have a injection of 3.75mg long-acting Triptorelin acetate (Dipherelin®, IPSEN, France) on the 1st-4th day of menstrual cycle.” NCT03809221 ↗ |
| Known as | Diphereline | “Triptorelin pamoate (Diphereline) 15mg will be used once per 12 weeks.” NCT04869371 ↗1“Diphereline (Triptorelin embonate)” NCT02940535 ↗ |
| Known as | FP-014 | “FP-014, 22.5 mg (Triptorelin Mesylate Injection, 22.5 mg)” NCT06795191 ↗ |
| Known as | Gonapeptyl | “For triggering, Choriogonadotropin-α (Ovitrelle©, 250 mcg/0.5 mL, Merck Serono S.p.A., Bari/Italy) 1 amp SC + Triptorelin Acetate (Gonapeptyl©, 0.1mg/mL, Ferring GmbH,...” NCT06396390 ↗3“Triptorelin pre-filled syringes (Gonapeptyl 0.1mg; Ferring GmbH, Germany) will be administered subcutaneously in three repeated doses 12 hours apart” NCT03169166 ↗ “gonadotropin agonist (triptorelin acetate, Gonapeptyl®) as a luteal phase supporter.” NCT03115307 ↗ “GnRH agonist (Triptorelin-Gonapeptyl® 0.3mg single dose)” NCT04157725 ↗ |
| Known as | Gonapetpyl | “with Triptorelin acetate 0.1 mg (Gonapetpyl daily; Ferring, Kiel, Germany)” NCT01590173 ↗ |
| Known as | Long-acting Triptorelin on pituitary down-regulation | “Long-acting Triptorelin on pituitary down-regulation” NCT02477566 ↗ |
| Known as | Pamorelin | “The active ingredient of Pamorelin® 11,25 mg is Triptorelin.” NCT00444639 ↗1“one subcutaneous depot of 22,5mg triptorelin (Pamorelin)” NCT05555017 ↗ |
| Known as | Pamorelin LA | “Applications of Triptorelin Pamoate (Pamorelin® LA 11.25 mg) in Patients With Advanced Prostate Cancer” NCT01257425 ↗1“e.g. Pamorelin® LA (Triptorelin) 11.25mg s.c.” NCT05746806 ↗ |
| Known as | Trelstar | “Triptorelin pamoate suspension (Trelstar 22.5 mg) injected intramuscularly in the buttock.” NCT01161563 ↗ |
| Known as | triptorelin (Diphereline SR 3 mg, Ibsen) | “triptorelin (Diphereline SR 3 mg, Ibsen)” NCT01764230 ↗ |
| Known as | Triptorelin acetate | “Participants will be administered with LHRHa (example, leuprolide, goserelin, triptorelin acetate) as a 3-monthly depot preparation within 3 days after randomization and the...” NCT04557059 ↗19“For triggering, Choriogonadotropin-α (Ovitrelle©, 250 mcg/0.5 mL, Merck Serono S.p.A., Bari/Italy) 1 amp SC + Triptorelin Acetate (Gonapeptyl©, 0.1mg/mL, Ferring GmbH,...” NCT06396390 ↗ “Pituitary suppression will be done using daily subcutaneous injection of triptorelin acetate ( Decapeptyl 0.1mg, Ferring, Germany). Starting from day 21 of the previous cycle” NCT03684824 ↗ “Ultra-long protocol group women will receive one intra-muscular administration of 11.25 mg GnRH agonist (triptorelin acetate) on the luteal phase of their menstrual cycle.” NCT03940807 ↗ “Decapeptyl® daily administration (Triptorelin acetate) and follicular puncture at 24, 30, 36 or 40 after administration.” NCT02244151 ↗ “Triptorelin acetate 3.75mg is administered via intramuscular injection once every four weeks.” NCT06487143 ↗ “gonadotropin agonist (triptorelin acetate, Gonapeptyl®) as a luteal phase supporter.” NCT03115307 ↗ “GnRH-agonist (Triptorelin acetate, decapeptyl 0.2 mg, Slough, United Kingdom)” NCT04407052 ↗ “with Triptorelin acetate 0.1 mg (Gonapetpyl daily; Ferring, Kiel, Germany)” NCT01590173 ↗ “leuprolide, goserelin, triptorelin acetate” NCT04181203 ↗ “Drug: triptorelin acetate” NCT01007851 ↗ |
| Known as | triptorelin acetate PR 1-month | “the standard of care, triptorelin acetate PR 1-month” PMID 35947347 ↗ Aug 2022 |
| Known as | Triptorelin embonate | “Diphereline (Triptorelin embonate)” NCT02940535 ↗ |
| Known as | triptorelin embonate (pamoate) | “Each patient received two consecutive intramuscular injections of triptorelin embonate (pamoate) 22.5 mg at an interval of 24 weeks.” PMID 19888782 ↗ 2009 |
| Known as | Triptorelin Mesylate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06795191 ↗ |
| Known as | triptorelin pamoate | “The main aim of this study is to assess the effectiveness and safety of the 6-month formulation of triptorelin pamoate in Chinese participants with locally advanced or...” NCT05590793 ↗9“A prolonged release formulation of triptorelin pamoate 22.5 mg 6-month formulation in D, L-lactide-co-glycolide polymers for single subcutaneous injection on Day 1 and Day 169” NCT05458856 ↗ “Applications of Triptorelin Pamoate (Pamorelin® LA 11.25 mg) in Patients With Advanced Prostate Cancer” NCT01257425 ↗ “Triptorelin pamoate 15mg is administered via intramuscular injection once every three months.” NCT06487143 ↗ “Triptorelin pamoate suspension (Trelstar 22.5 mg) injected intramuscularly in the buttock.” NCT01161563 ↗ “Triptorelin pamoate (Diphereline) 15mg will be used once per 12 weeks.” NCT04869371 ↗ “Triptorelin pamoate 11.25mg (Decapeptyl® SR)” NCT00564850 ↗ “Triptorelin Pamoate 11.25mg” NCT01715129 ↗ “Drug: Triptorelin pamoate” NCT00124514 ↗ “Triptorelin pamoate 15mg” NCT04736602 ↗ |
| Known as | Triptorelin SR | “A prospective, single-centre, single-arm, open label study of the long term use of a gonadotropin releasing hormone agonist (Triptorelin SR, 11.25 mg) in combination with...” PMID 32290838 ↗ Apr 2020 |
| Known as | triptorelin: Diphereline | “triptorelin: Diphereline” NCT02022228 ↗ |
| Known as | Tryptorelin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00503217 ↗ |
| Action | Inhibit | “Hormone therapy using triptorelin may fight prostate cancer by reducing the production of androgens.” NCT00003026 ↗ |
| Modality | Other / unclassified | “a Gonadotrophin Releasing Hormone Analogue” NCT00415246 ↗ |
| Route | Intramuscular | “triptorelin IM once a month” NCT00003734 ↗ |